Abstract
In searching for better anticonvulsant drug and the importance of semicarbazones and 2,5-disubstituted 1,3,4- oxadiazoles as anticonvulsant pharmacophore, a series of novel substituted semicarbazones were designed, synthesized and evaluated for their anticonvulsant activity. Among all the synthesized compounds, N1-(5-{2-[(2,6- dichlorophenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-hydroxyphenyl)(phenyl) methanone]-semicarbazone 12 emerged out as the most potent compound, showing considerable activity in maximal electroshock seizure (at 100 mg/kg after 0.5 h and at 300 mg/kg after 4.0 h) and subcutaneous pentylenetrtrazole model (at 300 mg/kg after 4.0 h) without any neurotoxicity (up to 300 mg/kg after 4.0 h). The results of the present study validated that the pharmacophore model with four binding sites is essential for anticonvulsant activity.
Keywords: 1,3,4-Oxadiazoles, Semicarbazones, Anticonvulsant activity, Neurotoxicity
Letters in Drug Design & Discovery
Title: Anticonvulsant Activity of A Novel Series of 2,5-Disubstituted 1,3,4-Oxadiazoles: Semicarbazones Based Pharmacophoric Model Studies
Volume: 6 Issue: 6
Author(s): Harish Rajak, Ravichandran Veerasamy, Pradeep Singour, Murli Dhar Kharya and Pradeep Mishra
Affiliation:
Keywords: 1,3,4-Oxadiazoles, Semicarbazones, Anticonvulsant activity, Neurotoxicity
Abstract: In searching for better anticonvulsant drug and the importance of semicarbazones and 2,5-disubstituted 1,3,4- oxadiazoles as anticonvulsant pharmacophore, a series of novel substituted semicarbazones were designed, synthesized and evaluated for their anticonvulsant activity. Among all the synthesized compounds, N1-(5-{2-[(2,6- dichlorophenyl)amino]benzyl}-1,3,4-oxadiazol-2-yl)-N4-[1-(4-hydroxyphenyl)(phenyl) methanone]-semicarbazone 12 emerged out as the most potent compound, showing considerable activity in maximal electroshock seizure (at 100 mg/kg after 0.5 h and at 300 mg/kg after 4.0 h) and subcutaneous pentylenetrtrazole model (at 300 mg/kg after 4.0 h) without any neurotoxicity (up to 300 mg/kg after 4.0 h). The results of the present study validated that the pharmacophore model with four binding sites is essential for anticonvulsant activity.
Export Options
About this article
Cite this article as:
Rajak Harish, Veerasamy Ravichandran, Singour Pradeep, Kharya Dhar Murli and Mishra Pradeep, Anticonvulsant Activity of A Novel Series of 2,5-Disubstituted 1,3,4-Oxadiazoles: Semicarbazones Based Pharmacophoric Model Studies, Letters in Drug Design & Discovery 2009; 6 (6) . https://dx.doi.org/10.2174/157018009789057571
DOI https://dx.doi.org/10.2174/157018009789057571 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued) Recent Advances in the Treatment of Neurogenic Erectile Dysfunction
Recent Patents on CNS Drug Discovery (Discontinued) “Epileptic Encephalopathy” of Infancy and Childhood: Electro-Clinical Pictures and Recent Understandings
Current Neuropharmacology Galanin: A Novel Therapeutic Target for Depression, Anxiety Disorders and Drug Addiction?
CNS & Neurological Disorders - Drug Targets 2D Pharmacophoric Design and Synthesis of Novel Pyrimidine Derivatives as Anticonvulsants
Current Bioactive Compounds Preface
Current Medical Imaging Agonists and Antagonists of Metabotropic Glutamate Receptors: Anticonvulsants and Antiepileptogenic Agents?
Current Neuropharmacology Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease
Current Neuropharmacology The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research 2,3-Disubtituted Thiazolidin-4-ones: Novel Class of Anticonvulsant Agents
Letters in Drug Design & Discovery Mood Disorders in Elderly Population: Neurostimulative Treatment Possibilities
Recent Patents on CNS Drug Discovery (Discontinued) Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Homocysteine in Neurological Disease: A Marker or a Cause?
CNS & Neurological Disorders - Drug Targets Sodium Valproate Induced Tremor in a Patient with Epilepsy and Down's Syndrome
Current Drug Safety Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets Endocannabinoids in the Central Nervous System: From Neuronal Networks to Behavior
Current Drug Targets - CNS & Neurological Disorders Coumarin-1,2,3-triazole Hybrid Molecules: An Emerging Scaffold for Combating Drug Resistance
Current Topics in Medicinal Chemistry Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells
Current Topics in Medicinal Chemistry Regeneration in a Degenerating Brain: Potential of Allopregnanolone as a Neuroregenerative Agent
Current Alzheimer Research Synthesis and Studies on Anticonvulsant and Antibacterial Activities of 1- Alkyl-4-(4H-1,2,4-triazol-4-yl)piperidine Derivatives
Letters in Drug Design & Discovery